Neurelis’ Valtoco Receives the US FDA’s Approval for Acute Treatment of Seizure Clusters
Shots:
- The US FDA has approved Valtoco for short-term treatment of acute repetitive seizures (seizure clusters) in pts (≥2yrs.) with epilepsy
- Approval was based on P-I/IIa trial assessing safety & PK of Valtoco, which showed favorable safety & efficacy with easy administration in pts who had episodes of frequent seizures; data was presented at CNS 2024 & AES 2024
- Valtoco is a proprietary diazepam formulation that utilizes Intravail tech to improve non-invasive intranasal absorption & delivery for acute treatment of intermittent, stereotypic seizure episodes distinct from a pts’s usual pattern
Ref: Prnewswire | Image: Neurelis
Related News:- Eisai, Biogen and BioArctic Report the EC’s Approval of Leqembi (lecanemab) for Early Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
